OBJECTIVES: New oral anticoagulants (NOACs) are available for the treatment and prevention of VTE, but evidence on their clinical effectiveness compared with existing treatments is limited. We compared the clinical effectiveness of edoxaban, dabigatran and rivaroxaban using adjusted standard dose warfarin (warfarin) as a common comparator in patients with index DVT. This research was conducted during a review of the company’s submission (CS) to the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal programme for the oral direct factor Xa inhibitor, edoxaban. METHODS: Randomised controlled trials (RCTs) for inclusion were identified using the CS for edoxaban (as part of Technology Appraisal [TA] 662). We assessed RCTs for comparability based on patient population, disease severity, and treatments received. We conducted a Bayesian MTC and explored fixed and random effects models. Odds ratio (OR) was the summary statistic for VTE recurrence and major bleed. RESULTS: The network of five RCTs formed a “radiating star”. The Deviance Information Criterion (DIC) and the residual deviance with the number of unconstrained data points for both outcomes showed fixed and random effects models were an equally good fit. Due to the small number of studies and the shape of the network, the results from the fixed effects model are presented. Results compared to warfarin were (OR>1 favours warfarin): VTE recurrence edoxaban OR 0.95 (95% Credible Interval [95%CrI]: 0.62–1.40), dabigatran OR 1.27 (95%CrI: 0.78–1.97), rivaroxaban OR 0.64 (95%CrI: 0.40–0.96); major bleed edoxaban OR 0.84 (95%CrI: 0.48–1.35), dabigatran OR 0.83 (95%CrI: 0.50–1.31), rivaroxaban OR 0.92 (95%CrI: 0.37–1.90). CONCLUSIONS: Rivaroxaban demonstrated a 36% reduction in risk of VTE recurrence compared to warfarin that was statistically significant at the 5% level. We did not identify other significant differences either when comparing NOACs to warfarin or when comparing NOACs with each other.